In addition, Tspan7 autoantibody can be used as a marker in type 1 diabetes and can distinguish individuals with latent autoimmune diabetes among adults characterized by the gradual decline in β-cell function, indicating its potential as a valuable target for immunotherapy in type 1 diabetes (McLaughlin et al., 2016; Walther et al., 2016; Shi et al., 2019). This evidence concerns the gene TSPAN7 and type 1 diabetes mellitus.